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Abstract
Background—Guidelines for post resection surveillance of colorectal cancer recommend a 
collection of the patient's history and physical examination, testing for carcinoembryonic antigen 
(CEA), and colonoscopy. No consistent guidelines exist for the use of abdominal computed 
tomography (CT) and position emission tomography (PET)/PET-CT. The goal of our study was to 
describe current trends, the impact of oncologic follow-up on guideline adherence, and the 
patterns of use of nonrecommended tests.
Methods—We used Texas Cancer Registry—Medicare-linked data (2000-2009) to identify 
physician visits, CEA testing, colonoscopy, abdominal CT, and PET/PET-CT scans in patients 
≥66 years old with stage I-III colorectal cancer who underwent curative resection. Compliance 
with guidelines was assessed with a composite measure of physician visits, CEA tests, and 
colonoscopy use from start of surveillance.
Results—In patients who survived 3 years, the overall compliance with guidelines was 25.1%. In 
patients seen regularly by a medical oncologist, compliance with guidelines increased to 61.5% 
compared with 8.8% for those not seen by a medical oncologist regularly (P < .0001). The use of 
abdominal CTand PET/PET-CT increased from 57.5% and 9.5%, respectively, in 2001 to 65.8% 
and 24.6% (P <.0001) in 2006. Patients who saw a medical oncologist were more likely to get 
cross-sectionalimagingthan those whodid not (P <.0001).
Conclusion—Compliance with current minimum guidelines for post treatment surveillance of 
colorectal cancer is low and the use of nonrecommended testing has increased over time. Both 
compliance and use of nonrecommended tests are markedly increased in patients seen by a 
medical oncologist. The comparative effectiveness of CT and PET/PET-CT in the surveillance of 
colorectal cancer patients needs further examination.
Colorectal cancer survivors are at high risk of cancer recurrence and development of new 
primary tumors. The primary goal of post treatment surveillance is to detect recurrences 
and/or new primary cancers at an early stage when they are potentially curable. Most 
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professional societies recommend a combination of physician visits, serum 
carcinoembryonic antigen (CEA) measurements, and colonoscopy after curative-intent 
treatment for early-stage colorectal cancer. Although the benefit of visits to one's physician 
has yet to be formally investigated, the onset of new symptoms in colorectal cancer 
survivors is often the first sign of cancer recurrence; consequently, a routine history 
collection and physical examinations are accepted as an important part of any post treatment 
cancer surveillance program.
CEA measurement is a cost-effective surveillance modality in patients with CEA-producing 
tumors.1,2 In some cases, an increase in CEA may be the first indicator of recurrence.3,4 
Although nearly all professional societies recommend CEA testing, the frequency and 
duration of testing are not agreed upon (Table I). In addition, the American Society of 
Clinical Oncology (ASCO) 2006 Update of Recommendations for the Use of Tumor 
Markers in Gastrointestinal Cancer and the 2003 European Group on Tumour Markers 
recommend surveillance CEA testing only for patients with stage II and III disease.5,6
Periodic surveillance of the colon by colonoscopy is useful in identifying new polyps or 
cancers and localized, asymptomatic recurrences amenable to curative treatment.7,8 A meta-
analysis of eight randomized controlled clinical trials in which the authors compared 
different intensity surveillance in colorectal cancer survivors demonstrated a survival benefit 
and a greater proportion of recurrences amenable to surgical resection in patients undergoing 
colonoscopic surveillance.9
Before 2002, there were no published data on the use of computed tomography (CT) scans 
for post treatment surveillance. Since then, several studies have demonstrated a survival 
benefit for CT scanning of the abdomen to detect liver metastases. The improved survival 
has been attributed to the benefit of metastasectomy in patients with isolated liver 
metastases.10-14 The efficacy of PET/PET-CT scans in post treatment surveillance has not 
been evaluated.
Current guidelines based on these data from the ASCO, the American Gastroenterological 
Association, the American Society of Colon and Rectal Surgeons, the National 
Comprehensive Cancer Network, the American Society for Gastrointestinal Endoscopy, and 
the American Cancer Society and U.S. Multi-Society Task Force on Colorectal Cancer are 
summarized in Table I.10,15-17
Our study uses Texas Cancer Registry and linked Medicare claims data to evaluate guideline 
compliance for physician visits, CEA testing, and colonoscopy. We also evaluate the use of 
CT scans of the abdomen, where recommendations are more ambiguous, as well as the use 
of PET and/or PET-CT, which are not currently recommended. Additionally, we analyzed 
physician follow-up patterns and the use of tests stratified by provider medical specialty to 
determine if patterns of care were influenced by provider specialty.
METHODS
The Institutional Review Board at the University of Texas Medical Branch determined this 
study to be exempt from review. The Texas Department of State Health Services approved 
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the study as did the privacy review board of the Centers for Medicare and Medicaid 
Services.
Data source
We used Texas Cancer Registry (TCR) and linked Medicare data from 2000 to 2009. The 
TCR is a statewide population-based registry that serves as the foundation for measuring the 
Texas cancer burden, comprehensive cancer control efforts, health disparities, progress in 
prevention, diagnosis, treatment, and survivorship, as well as supports a wide variety of 
cancer-related research.18 Medicare data include information on inpatient hospital stays, 
physician services, hospital outpatient services, and hospice use.19 Data use agreements 
were signed with both data providers.
Cohort selection
The details of the cohort selection are shown in Fig 1. We selected patients with resected 
first primary colorectal adenocarcinoma between 2001 and 2006. This allowed us to 
evaluate claims (2000–2009) in the year before diagnosis to determine comorbidity and to 
follow all patients for 3 years after definitive resection. A total of 12,381 beneficiaries met 
the inclusion criteria. Of these, 8,080 survived at least 3 years from the start of the 
surveillance period.
Incident cancers were identified from TCR. Adenocarcinoma was identified using 
International Classification of Diseases for Oncology, 3rd Edition histology codes 8000, 
8050, 8051, 8052, 8010, 8021, 8022, 8140, 8141, 8143, 8145, 8147, 8210, 8211, 8220, 
8221, 8230, 8260, 8261, 8262, 8263, 8430, 8440, 8470, 8471, 8480, 8481, 8490, 8550, 
8551, 8570, 8571, 8572, 8573, 8574, and 8575. Definitive colorectal resection was identified 
from the Medicare claims (Medicare Provider Analysis and Review, carrier, outpatient 
Standard Analytical File) using International Classification of Diseases, Ninth Revision 
Clinical Modification (ICD-9-CM) procedure codes (45.71-45.76, 45.79, 45.81-45.83, 
17.31-17.36, 17.39, 48.41-48.43, 48.49-48.52, 48.59-48.65, and 48.69) and Current 
Procedural Terminology, Fourth Edition (CPT-4) codes (44140-44147, 44150-44153, 
44160, 44204-44208, 44210, 44155-44158, 45110-45114, 45116, 45119-45121, 45123, 
45126, 45160, 45170, 45171, 45172, 44120-44212, 45395, and 45397). These codes 
included colon and rectal resections, both open and laparoscopic with or without colostomy. 
Patients who underwent stoma formation without resection were not included.
Surveillance period and definition of recurrence
The surveillance period began 90 days after definitive colorectal surgery. All patients were 
followed for 3 years or until death in the claims data. The 90-day lag before the start of the 
surveillance period was used to exclude tests done for postoperative complications and 
routine postoperative physician visits not for surveillance purposes. Of the 12,381 patients, 
91.2% were alive at the beginning of the surveillance period. A total of 8,080 patients 
survived 3 years after the start of the surveillance period. Observation of guidelines and the 
use of nonrecommended tests were measured in patients surviving for the entire 3-year 
surveillance period.
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Outcome measures and covariates
Medicare claims data in inpatient, outpatient, and carrier files were examined for receipt of 
procedures of interest using relevant ICD-9-CM or CPT-4 codes. Procedures included 
physician office visits (Evaluation and Management CPT-4 codes: 99201-99215, 99241- 
99245), CEA (CPT-4: 82378), colonoscopy (CPT-4: 44388, 44389, 44392-44394, 45378, 
45380, 45382-45385, G0105; ICD-9-CM: 45.23, 45.25, 45.41, 45.42, 45.43, 48.36), 
abdominal/pelvic CT scan (CPT-4: 72191-72194, 74150, 74160, 74170, 74175, 75635), 
PET/PET-CT scan (CPT-4: 78811-78816, G0213, G0214, G0215, G0163, G0231), and 
abdominal ultrasound (CPT-4 codes: 76700 and 76705; ICD-9-CM codes: 88.76, 88.74, and 
88.79). Duplicated claims for the same procedure on the same date of service were deleted 
such that each test was counted only once.
We had two primary outcome measures: overall compliance with current guidelines and use 
of nonrecommended surveillance tests (specifically CT abdomen/pelvis, PET/PET-CT, and 
ultra-sound). On the basis of a composite measure previously used by Cooper et al,20 
patients were considered as complying with guidelines if they had: (1) two or more 
physician visits per year for 3 years, (2) two or more CEA tests per year for 2 years, and (3) 
at least one colonoscopy in the 3-years surveillance period. We also evaluated compliance 
with the individual measures included in the composite measure to understand which 
components contributed to lack of compliance. In addition to obtaining overall physician 
visits, we evaluated physician visits by specialty using the Medicare Health Care Financing 
Administration specialty claims codes. We categorized specialty as primary care physician 
(PCP: included general practitioner [01], family practice [08], internal medicine [11], 
geriatrician [38]), medical oncolo-gist (medical oncology [90], hematology/oncology [83]), 
radiation oncologist (92), gastroenterologist (10), and surgeon (general surgeon [02], 
surgical oncologist [91], colorectal surgeon [28]). We evaluated both “any visit” by a 
specific specialist in the 3-year surveillance period as well as “regular physician visits” 
defined as two or more visits by the same type of physician every year for the 3-year 
surveillance period.
Covariates
Sociodemographic characteristics included age, sex, socioeconomic status, and race/
ethnicity. Charlson comorbidity index was used as a measure of patient comorbidity. Tumor 
characteristics included site (colon vs rectum), stage (local vs regional), tumor size, nodal 
status, and tumor differentiation. For patients with tumors classified as “rectosigmoid” 
(8.1% of the cohort) in TCR, we included them as “rectal” if they underwent radiation either 
before or after surgery and as “colon” if they did not. Localized disease was confined to the 
bowel wall, whereas regional disease extended to adjacent organs or regional lymph nodes. 
All patients underwent surgical resection. The percentage of patients receiving adjuvant 
chemotherapy was determined for the overall cohort. For patients with rectal cancer, the 
percentage of patients receiving adjuvant or neoadjuvant radiation was determined. 
Recurrence after surgery was defined as treatment with nonadjuvant chemotherapy and/or 
radiation (starting more than 6 months after surgery or a new course given after adjuvant 
therapy was completed), a second colorectal resection for a primary diagnosis of colorectal 
cancer, or admission to hospice.
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We calculated summary statistics for the overall cohort and measured the unadjusted 
association between patient, tumor, and treatment characteristics and receipt of guideline 
adherent post-treatment surveillance for the composite measure as well as the individual 
components. Overall and disease-specific survival was calculated for the whole cohort as 
well as the colon and rectal subgroups. The overall use of nonrecommended tests was 
evaluated. We used a Cochran-Armitage test for trend to evaluate trends in compliance or 
use of nonrecommended tests over time. Multivariate logistic regression was used to 
determine factors independently associated with the receipt of guideline adherent and non-
recommended surveillance. Both overall compliance and use of nonrecommended tests were 
evaluated in the 8,080 patients who survived the entire surveillance period, consistent with 
the Cooper study.20
For colonoscopy and CEA measurements we used a Kaplan-Meier time-to-event analysis to 
evaluate patterns of regular surveillance. This analysis included all 12,381 patients. We 
measured the percent of patients undergoing colonoscopy or CEA from the start of the 
surveillance period. Patients were censored when they recurred or died of any cause without 
documented recurrence as defined previously as they were no longer “at risk” or eligible for 
surveillance. This allowed us to measure overall compliance with colonoscopy and CEA 
until death or recurrence in all 12,381 patients, to evaluate the median time to the first test, 
and to evaluate the percentage of patients getting the test within the recommended time 
frame. In addition, it allowed us to assess regular surveillance. Conditional on receiving a 
first test, we were able to assess the time from the first to second test. All P values were 
from two-sided tests. All analyses were performed with SAS version 9.2 (SAS Inc, Cary, 
NC).
RESULTS
Patient, tumor, and primary treatment characteristics (Table II)
A total of 12,381 patients (mean age 77.1 ± 7.1 years; 53.2% female) met our inclusion 
criteria; 85.9% of patients were white, 8.1% black, and 4.5% Hispanic. The majority of 
patients had a Charlson comorbidity score of zero (58.8%). Eighty percent (86.7%) of 
cancers were in the colon of which 43.1% were in the right colon, 33.0% in the left colon, 
6.9% in the transverse colon, and 3.7% were unspecified. The remaining 13.3% were rectal 
cancers. Surveillance Epidemiology and End Results stage was local in 48.2% and regional 
in 51.8% of patients. The remaining tumor characteristics are shown in Table II.
All patients underwent resection of the primary tumor. Adjuvant chemotherapy was 
administered to 30.4% of patients. A total of 46.1% of those with regional disease received 
adjuvant chemotherapy compared with 13.5% for local disease (P < .0001). In rectal cancer 
patients, 46.5% were treated with adjuvant chemotherapy and 30.2% received adjuvant 
radiation. Neoadjuvant chemoradiation was administered to only 4.0% of rectal cancer 
patients.
Vargas et al. Page 5














The overall 5-year survival rate for the cohort (N = 12,381) was 53.0%. The 5-year survival 
was 52.9% and 53.6% for colon and rectal primaries, respectively. The 5-year disease 
specific survival was 78.0% for colon and 76.2% for rectal primaries. A total of 11,290 
patients (91.2%) survived to the beginning of the surveillance period and 8,080 patients 
(65.3%) survived 3 years from the start of the surveillance period, which began 90 days after 
surgery. The patient, tumor, and treatment characteristics for the 8,080 patients surviving 
three years are also shown in Table II. As would be expected, patients who survived 3 years 
were more likely to be younger, healthier, and had localized disease. A total of 39.4% of 
patients experience a recurrence of disease during the study period. Most recurrences 
(76.9%) were identified by treatment with nonadjuvant chemotherapy and/or radiation 
(starting more than 6 months after surgery or a new course given after adjuvant therapy was 
completed), 21.4% were identified upon referral to hospice, 1% were identified when they 
underwent a second surgical resection of colorectal cancer, and less than 1% were identified 
when they died from colon cancer, without previous evidence of recurrence and likely 
represent untreated recurrences.
Compliance with current guidelines (Table III)
Overall compliance (composite measure)—In patients surviving 3 years, compliance 
with the composite measure based on current guideline recommendations was 25.1% (Table 
III). Although it was statistically significant, overall compliance only improved from 20.8% 
in 2001 to 25.7% in 2007 (Fig 2, P = .018).
Physician visits—Of the three components, compliance with office visits was the highest 
(Table III), with 85.4% of patients seeing a physician at least twice a year for the 3-year 
surveillance period. A physician evaluated 98.9% of patients at least one time in the 
surveillance period. Beneficiaries most commonly saw PCPs, medical oncologists, surgeons, 
and gastroenterologists in the follow-up period (Table IV), and many patients were co-
followed with 50.4% of patients seeing both an oncologist and a PCP. A PCP alone saw 
36.6% of patients and a medical oncologist alone saw 7.0% of patients. Regular physician 
visits (two visits per year for 3 years for individual specialist/physician types) were most 
common for medical oncologists and PCPs. A total of 30.9% of patients were regularly seen 
by a medical oncologist, 46.7% by a PCP, 3.9% by a surgeon, 1.5% by a gastroenterologist, 
and less than 1% by a radiation oncologist (Table IV).
CEA—Measurement of serum CEA twice a year for 2 years was low at 29.5% (Table II) 
and was relatively stable over time. A total of 62.1% of patients had at least one CEA in the 
3-year surveillance period, and 34.6% had one per year for the 3 years. Of the 5,059 patients 
who had a serum CEA drawn during the first year, 80.0% received a second within a year of 
the first. The median time between the first and second measurement was 3.7 months, 
suggesting regular surveillance in those who were tested.
Colonoscopy—During the 3-year surveillance period, 75.3% of beneficiaries had at least 
one colonoscopy (Table III). Colonoscopy rates decreased slightly over the time period from 
75.9% in 2001 to 73.0% in 2006 (Fig 2, P = .037). In a Kaplan-Meier analysis, from the start 
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of surveillance, the median time to first colonoscopy was 11.3 months, with 53.7% of 
patients having a colonoscopy by the end of the first year and 75.3% by the end of the third 
year of surveillance (Fig 3, A). In the patients who had a first colonoscopy after curative 
intent treatment, the median time from first colonoscopy to second was 27.6 months, and 
58.0% of patients had a second colonoscopy within 3 years as recommended by most 
societies (Fig 3, B). After the first colonoscopy, there are peaks in colonoscopy rates at the 
1-, 2-, and 3-year time points, suggesting that practice patterns may differ from the 
guidelines.
Factors predicting compliance with guidelines (Table V and Table VI)
Table V shows the unadjusted guideline compliance (composite and individual measures) by 
patient and tumor characteristics. Patients who were younger, presented with regional 
disease, and had seen a medical oncologist were more likely to comply with the composite 
guidelines. Compliance increased to 61.5% in patients who were followed regularly by a 
medical oncologist compared with 8.8% in patients who were not followed regularly (P < .
0001).
Compliance with CEA serum testing (twice a year for 2 years) was more likely to occur in 
younger, healthier patients, those with poorly differentiated tumors, regional disease, rectal 
cancers, and in those who were followed regularly by a medical oncologist or PCP. Our 
study shows double the rate of guideline-compliant CEA testing in patients with regional 
disease, but even in this group, CEA testing twice annually for 2 years was only achieved in 
41.0% of patients. Patients younger than 70 years of age were more than twice as likely to 
have regular CEA measurements compared with those 85 years and older. CEA testing 
showed the greatest improvement in compliance with regular medical oncology visits. Those 
who were seen regularly received CEA testing 70.5% of the time compared to 11.1% in 
those who did not see an oncologist regularly (P < .0001).
Factors associated with compliance with colonoscopy recommendations were younger age, 
white race, Charlson comorbidity score of 0 or 1, and physician follow-up. Similar to CEA 
testing, compliance improved more dramatically when a medical oncologist was involved in 
follow-up care. Compliance with colonoscopy improved to 86.7% when a medical 
oncologist saw patients regularly. Patients not seen regularly by an oncologist received 
colonoscopy only 70.1% of the time (P < .0001). On multivariate analysis, male sex, 
younger age, regional disease, regular medical oncology visits, and regular PCP visits were 
associated with overall guideline compliance (Table VI).
Use of nonrecommended tests
The use of CT of the abdomen, PET and/or PET-CT increased sharply from 2001 to 2006. 
In 2001, the use of CT and PET/PET-CT was 57.5% and 9.5% respectively. This increased 
to 65.8% and 24.6% in 2006 (P < .0001; Fig 4). Factors associated with use of these imaging 
modalities were similar to those associated with guideline compliance (Table VI). Patients 
evaluated by a medical oncologist at any point were more likely to obtain CT scans and 
PET/PET-CT scans. Patients with regular PCP visits were more likely to have CT scans, but 
not PET/PET-CT (Table VI). CT and PET/PET-CT were also more common with increasing 
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year of diagnosis, in patients with rectal primaries, in patients with regional disease, and for 
PET/PET-CT, in those with poorly differentiated tumors.
We found evidence of regular use of abdominal CT and PET/PET-CT. 50.5% of patients 
who received a CT scan received a second one within a year and 33.0% of patients who 
received a PET/PET-CT scan received a second one within a year. Only 15.9% (n = 1,287) 
had an abdominal ultra-sound in the 3-year surveillance period. Of those patients who had 
one abdominal ultrasound, a second abdominal ultrasound was performed in 19.8% of 
patients.
DISCUSSION
Compliance with the minimal recommendations for post treatment surveillance of colorectal 
cancer occurred in only 25% of patients with resected primary colorectal cancer. The 
poorest compliance occurred with serum CEA measurements, with better compliance for 
physician visits and colonoscopy. Although underuse of recommended testing is evident, 
there is also a pattern of testing in excess of the recommended guidelines in this patient 
population. The use of PET scans and PET/CT scans increased during the study period 
despite no professional society recommendations for PET/PET-CT use in post treatment 
surveillance. Similarly, CT scan use increased over time, although it was not recommended 
for post treatment surveil-lance until near the end of our study period in 2005. The use of 
nonrecommended tests correlates with guideline compliance, with patients adhering to 
guidelines being more likely to undergo additional testing. Additionally, there was a 
difference in guideline compliance on the basis of which medical specialist provided post 
treatment surveillance care. Evaluation by a medical oncologist during the follow up period 
had the strongest association with improvement of guideline compliance. However, medical 
oncologist follow-up was also associated with the greatest increase in the use of 
nonrecommended tests.
Our results show minimal improvement over previous population-based data on guideline 
compliance. An earlier population based study, using Surveillance Epidemiology and End 
Results—Medicare-linked data and an identical composite measure of guideline compliance, 
found that in patients diagnosed between 2000 and 2001, overall guideline compliance was 
only 17.1%.20 The authors also evaluated the use of cross-sectional imaging studies in this 
population. Imaging in excess of guidelines was defined, by the authors, as the receipt of ≥1 
CTscan and/or ≥1 PETscan in patients who met overall guideline recommendations. 
Guideline recommendations were exceeded in 22.7% of patients. Similar to our results, 
younger age and regional tumors were found to be predictors of both compliance and 
overuse of imaging studies.20 Our study demonstrates further increase in the use of 
nonrecommended tests.
There is disagreement regarding the benefit of serial CEA measurements in surveillance. 
Although some studies suggest it is a cost-effective surveillance strategy,1,2 others have 
documented negligible improvements in survival.21-23 Our study demonstrated overall rates 
of CEA testing compliance to be only 29.5%. This is lower than the 46.7% demonstrated in 
the earlier population-based study by Cooper et al20 and the 32.8% documented in a Swiss 
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cohort study.24 Although initially recommended in all patients, the 2006 ASCO guidelines 
recommended CEA testing only in stage II-III colorectal cancers.6 Our study includes stage 
I cancers and therefore may overestimate noncompliance. However, compliance was <50% 
even in patients with regional disease. Serial CEA measurements may not be useful for 
surveillance in patients whose primary tumor was a non-CEA—producing tumor. Since we 
could not identify these patients in TCR-Medicare data, we may be overestimating 
noncompliance. However, the percentage of non-CEA—producing tumors should be low, as 
it is estimated that approximately 60–90% of recurrent colon cancers produce CEA.24,25
Screening for liver metastases may be performed with abdominal ultrasonography, CT, or 
PET/PET-CT. In Europe, abdominal ultrasound has proven an effective imaging modality in 
the detection of hepatic metastases amenable to surgical resection.26-28 However, in their 
2005 update, the American Society of Clinical Oncology did not find sufficient evidence 
supporting the recommendation for abdominal ultrasound in post treatment surveillance.10 
Only 16% of patients in our study underwent abdominal ultrasound in the 3-year 
surveillance period.
Three meta-analyses and one prospective randomized trial identified a benefit in the 
detection of resectable liver metastases and improved survival in patients undergoing 
periodic abdominal CT scans.11-14 Currently, CT scanning of the chest, abdomen, and pelvis 
is recommended for patients at high risk for recurrence, such as those with poorly 
differentiated tumors or those whose pathology demonstrates lymphovascular invasion. 
Because cross-sectional imaging was not recommended during most of our study period, we 
considered the use of CT in post treatment surveillance in excess of the recommended 
guidelines. However, it is possible that the increase we observed in CT scan use may be due 
to the initial findings of benefit first published in 2002 and may represent indicated studies.
In a study evaluating the changes in use and the costs of diagnostic imaging studies among 
Medicare beneficiaries with cancer, researchers found that imaging studies contribute less 
than 6% of total health care expenditure but the costs for CT scans, PET, and MRI are 
increasing twice as fast as the overall cost of cancer care.29 Consistent with these findings, 
the use of PET/PET-CT increased sharply during the study period and in 2007 was 
performed in nearly a quarter of survivors. Although PET-CT has been found to be more 
sensitive compared with CT in the detection of recurrence, new primary tumors, and 
metastatic disease in several trials,30-33 there is a paucity of published data on the added 
value of PET/PET-CT in the detection of recurrence or metastatic disease in patients being 
followed in a surveillance program.34
Further studies are needed to determine the comparative effectiveness of various post 
treatment surveillance strategies on overall and disease-specific survival, disease-free 
survival, and cost. The data generated in our study are the first step in using observational 
data to evaluate the comparative effectiveness of CT and/or PET-based surveillance 
strategies as well as other less expensive modalities, such as abdominal ultrasonography. 
However, studying the comparative effectiveness of these strategies in an observational 
dataset presents many challenges. A simple comparison of the percent of patients with 
detected recurrence in the compliant and noncompliant groups is subject to significant 
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selection bias. Advanced statistical methods such as propensity score analyses or 
instrumental variable analyses will be needed to control for selection bias when evaluating 
outcomes such as overall survival, time to recurrence, and disease-free survival.
Involvement of both medical oncologists and PCPs in the care of colorectal cancer patients 
has been shown to improve the receipt of non-cancer related health care for chronic medical 
conditions.35,36 It has also been demonstrated that colorectal cancer survivors who did not 
see a medical oncologist were less likely to undergo surveillance colonoscopy when 
compared to patients seen by an oncologist (27.6% vs 46.7%).36 In our study, compliance 
with surveillance guidelines was markedly improved in patients followed regularly by a 
medical oncologist compared with patients not followed regularly by a medical oncologist 
(61.5% vs 8.8%).
Although our study highlights the importance of involvement of a medical oncologist in the 
follow-up of colorectal cancer survivors, we hesitate to conclude that a medical oncologist 
should follow all colorectal cancer patients. Compliance with guidelines is improved with 
medical oncology follow-up; however, the use of nonrecommended tests is also increased. 
Moreover, with the increasing number of older patients and prolonged survival of colorectal 
cancer survivors, it is not feasible for medical oncologists to follow all patients long-term. 
We need to educate providers caring for colorectal cancer patients and improve the 
communication between oncologists and primary care providers in the transfer of 
survivorship care back to the PCPs. In the current era of highly specialized medicine, PCPs 
may erroneously assume that an oncologist is involved and consequently do not take on post 
treatment surveillance care.
Our study has several limitations. We did not investigate the indication for medical services. 
Compliance with physician visits may be overestimated because these services may have 
been rendered as part of care not related to the patient's diagnosis of colorectal cancer. 
Likewise, specific billing claims for physical examination components, such as digital rectal 
exams are not available; therefore, we cannot evaluate the completeness or thoroughness of 
the physical examinations performed. Similarly, imaging may have been prompted by 
symptoms or may have been obtained to diagnose complications related to treatment. 
Therefore, the use of CT and PET/PET-CT may be overestimated. Despite this limitation, 
we would not expect the proportion of symptomatic patients to change over time, so the 
increasing trend remains striking. Clinically, a PET scan may be obtained to work-up an 
elevated CEA when a CT scan does not demonstrate a recurrence. We did not analyze the 
number of PET/PET-CTs obtained after a CTscan. In addition, there may be reasons for lack 
of surveillance in older patients. Some patients may be deemed too frail or have too many 
comorbid conditions to undergo retreatment of a recurrent cancer and therefore post 
treatment surveillance is not viewed to be of benefit. Likewise, older patients may decline 
surveillance because they may be unwilling to undergo retreatment even if it is 
recommended by their physician.
Our study demonstrates inadequate post treatment surveillance in older patients after 
resection for early stage primary colorectal cancer. Given the prevalence of colorectal cancer 
and recurrence rates of 30–40%, assurance of appropriate post-treatment surveillance is an 
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important health care issue. Improved compliance can be achieved through standardization 
of guidelines across societies. Such standardization needs to be driven by quality studies 
evaluating the comparative effectiveness of current and newer surveillance strategies and 
may vary based on initial tumor stage. Improved education for nononcologic physicians 
following colorectal cancer survivors, improved communication, and transition of care from 
medical oncologists to PCPs after completion of adjuvant therapy may improve the quality 
of surveillance in this vulnerable population.
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Cohort selection. HMO, Health maintenance organization.
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Trends in compliance with composite measure guidelines, physician visits, serum CEA 
measurements, and colonoscopy from 2001 to 2006.
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Time to first and second colonoscopies. (A) Time to first colonoscopy. (B) Time from first to 
second colonoscopy.
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Trend in use of CT and PET/PET-CT from 2001 to 2006.
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Table II
Patient, tumor, and primary treatment characteristics
Patient demographics n = 12,381 n = 8,080
Age (y), mean ± SD 77.1 ± 7.1 75.7 ± 6.5
Female sex
* 6,590 (53.2) 4,337 (53.7)
Race (n = 12,365)
    White 10,621 (85.9) 6,985 (86.5)
    Black 998 (8.1) 614 (7.6)
    Hispanic 550 (4.5) 339 (4.2)
    Other 196 (1.6) 134 (1.7)
Charlson comorbidity score
    0 7,284 (58.8) 5,197 (64.3)
    1 2,867 (23.2) 1,786 (22.1)
    2 1,202 (9.7) 661 (8.2)
    3 1,028 (8.3) 436 (5.4)
Tumor characteristics
    Colon cancer 10,734 (86.7) 6,427 (79.5)
    Rectal cancer 1,647 (13.3) 1,653 (20.5)
    Local 5,970 (48.2) 4,422 (54.7)
    Regional 6,411 (51.8) 3,658 (45.3)
    Tumor size (N = 10,095), mean, mm 44.3 42.3
    Lymph node status (N = 11,342/7,405)
        Positive 3,862 (34.1) 2,050 (27.7)
        Negative 7,480 (66.0) 5,355 (72.3)
        Poorly differentiated 2,164 (17.5) 1,161 (14.4)
Site
    Right 5,339 (43.1) 3,439 (42.6)
    Left 4,081 (33.0) 2,864 (35.5)
    Transverse 854 (6.9) 528 (6.5)
    Unspecified 460 (3.7) 292 (3.6)
Treatment
    Adjuvant chemotherapy (yes) 3,760 (30.4) 2,656 (32.9)
    Adjuvant radiation (rectal cancer only) 310 (21.2) 200 (20.9)
    Neoadjuvant chemotherapy (yes) 665 (5.4) 456 (5.6)
    Neoadjuvant radiation (rectal cancer only) 717 (29.2) 505 (30.5)
*
Values are n (%) unless otherwise indicated.
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Table III
Compliance with recommended guidelines
Compliance Overall, N = 8,080
PCP (regular follow-up),
*
 n = 3,775 Medical oncologist (regular follow-up),
*
 n = 2,498
Composite measure† 2,029 (25.1) 1,046 (27.7) 1,537 (61.5)
Office visits 6,898 (85.4) 3,775 (100) 2,498 (100)
CEA 2,382 (29.5) 1,201 (31.8) 1,761 (70.5)
Colonoscopy 6,080 (75.3) 2,998 (79.4) 2,166 (86.7)
CEA, Carcinoembryonic antigen.
*
Two visits per year for 3 years.
†
Values are n (%) unless otherwise indicated.
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Table IV
Physician visits during 3-year follow-up, N = 8,080
Physician specialty Any visit Regular visits
*
Any physician 7,998 (98.9)† 6,898 (85.4)
Medical oncologist 4,642 (57.5) 2,498 (30.9)
PCP 7,032 (87.0) 3,775 (46.7)
Surgeon 4,554 (56.4) 313 (3.9)
Radiation oncologist 5,83 (7.2) 18 (0.2)
Gastroenterologist 3,340 (41.3) 123 (1.5)
PCP, Primary care physician.
*
Regular visits = ≥2 visits per year.
†
Values are n (%) unless otherwise indicated.
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Table V
Bivariate analysis of factors predicting compliance with composite guidelines, CEA measurements, and 
colonoscopy
Factor (P value) Guideline compliance Serum CEA measurement compliance Colonoscopy compliance
Age, years*,†,‡
    66–69 530 (32.5)§ 597 (36.6) 1,385 (84.9)
    70–74 642 (29.6) 739 (34.0) 1,774 (81.7)
    75–79 527 (25.8) 619 (30.3) 1,586 (77.6)
    80–84 249 (18.3) 301 (22.1) 925 (68.0)
    ≥85 81 (9.3) 126 (14.4) 410 (46.8)
Sex
    Male 927 (24.8) 1,095 (29.3) 2,851 (76.2)
    Female 1,102 (25.4) 1,287 (29.7) 3,229 (74.5)
Race‡
    White 1,789 (25.6) 2,083 (29.8) 5,335 (76.4)
    Black 138 (22.5) 163 (26.6) 434 (70.7)
    Hispanic 70 (20.7) 93 (27.4) 214 (63.1)
    Other 31 (23.1) 41 (30.6) 92 (68.7)
Cancer type*,†
    Colon 1,578 (24.6) 1,842 (28.7) 4,854 (75.5)
    Rectal 451 (27.3) 540 (32.7) 1,226 (74.2)
Differentiation*,†
    Poorly differentiated 363 (31.3) 429 (37.0) 860 (74.1)
    Well differentiated 1,666 (24.1) 1,953 (28.2) 5,220 (75.4)
Stage*,†,‡
    Local 763 (17.3) 882 (20.0) 3,375 (76.3)
    Regional 1,266 (34.6) 1,500 (41.0) 2,705 (74.0)
Charlson comorbidity score*,†,‡
    0 1,380 (26.6) 1,610 (31.0) 3,997 (76.9)
    1 430 (24.1) 507 (28.4) 1,348 (75.5)
    2 141 (21.3) 171 (25.9) 457 (69.1)
    ≥3 78 (17.9) 94 (24.6) 278 (63.8)
Medical oncologist visits*,†,‡
    Regular medical oncologist 1,537 (61.5) 1,761 (70.5) 2,166 (86.7)
    No regular medical oncologist visit 492 (8.8) 621 (11.1) 3,914 (70.1)
PCP visits*,†,‡
    Regular PCP visits 1,046 (27.7) 1,201 (31.8) 2,998 (79.4)
    No regular PCP visits 983 (22.8) 1,181 (27.4) 3,082 (71.6)
Year of diagnosis*,†
    2001 281 (20.8) 325 (24.0) 1,026 (75.9)
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Factor (P value) Guideline compliance Serum CEA measurement compliance Colonoscopy compliance
    2002 361 (25.4) 416 (29.2) 1,085 (76.2)
    2003 390 (27.2) 461 (32.2) 1,092 (76.3)
    2004 353 (26.3) 415 (30.9) 1,017 (75.6)
    2005 338 (25.3) 404 (30.3) 990 (74.2)
    2006 306 (25.7) 361 (30.3) 870 (73.0)
Education*,†,‡
    Quartile 1 440 (23.0) 520 (27.2) 1,362 (71.2)
    Quartile 2 444 (22.9) 545 (28.1) 1,447 (74.6)
    Quartile 3 543 (26.8) 621 (30.7) 1,547 (76.5)
    Quartile 4 585 (27.3) 676 (31.6) 1,674 (78.2)
Income*,†,‡
    Quartile 1 406 (21.4) 497 (26.2) 1,354 (71.3)
    Quartile 2 452 (22.9) 536 (27.2) 1,456 (73.8)
    Quartile 3 560 (27.7) 647 (32.0) 1,551 (76.7)
    Quartile 4 594 (28.1) 682 (32.2) 1,669 (78.8)
P values for χ2 analysis representing any difference within categories.
CEA, Carcinoembryonic antigen; PCP, primary care physician.
*
P < .02 for guideline compliance.
†
P < .02 for CEA compliance.
‡
P < .02 for colonoscopy compliance.
§
Values are n (%) unless otherwise indicated.
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Table VI
Multivariate analysis of factors predicting compliance with guidelines and use of CT and PET/PET-CT
Factor (Ref) Guideline compliance OR (95% CI) CT use OR (95% CI) PET/PET-CT use OR (95% CI)
Age (≥85 years)
    66–69 2.80 (2.09–3.74) 1.85 (1.54–2.21) 2.54 (1.89–3.42)
    70–74 2.55 (1.92–3.39) 1.71 (1.44–2.03) 2.46 (1.84–3.29)
    75–79 2.47 (1.85–3.28) 1.59 (1.34–1.88) 2.27 (1.69–3.04)
    80–84 1.84 (1.36–2.50) 1.28 (1.07–1.53) 1.72 (1.26–2.35)
Sex (male) 1.14 (1.00–1.29) 0.99 (0.90–1.09) 0.84 (0.75–0.96)
Race (Hispanic)
    Black 1.40 (0.94–2.07) 0.95 (0.70–1.28) 0.87 (0.60–1.26)
    White 1.31 (0.94–1.82) 0.88 (0.69–1.14) 0.94 (0.69–1.28)
    Other 1.13 (0.63–2.03) 0.92 (0.59–1.44) 1.14 (0.67–1.95)
Cancer (rectum) 1.03 (0.87–1.22) 0.60 (0.51–0.69) 0.61 (0.52–0.71)
Poorly differentiated (no) 1.09 (0.92–1.29) 1.17 (1.01–1.35) 1.25 (1.06–1.47)
Stage (local) 1.48 (1.30–1.68) 1.69 (1.53–1.87) 1.69 (1.49–1.91)
Charlson comorbidity score (0)
    1 0.96 (0.83–1.12) 1.12 (1.00–1.27) 0.94 (0.81–1.10)
    2 0.76 (0.60–0.96) 1.18 (0.98–1.41) 1.11 (0.88–1.38)
    ≥3 0.75 (0.55–1.01) 1.01 (0.82–1.25) 0.83 (0.62–1.12)
Medical oncologist visit (no) 14.22 (12.49–16.18) 3.75 (3.31–4.25) 4.30 (3.79–4.88)
PCP visit 2×/3 years (no) 1.51 (1.33–1.72) 1.27 (1.15–1.40) 1.07 (0.94–1.21)
Year of diagnosis (per year) 1.02 (0.98–1.06) 1.07 (1.04–1.10) 1.23 (1.18–1.27)
Education (Q1)
    Q2 1.03 (0.86–1.24) 1.06 (0.92–1.22) 0.72 (0.61–0.87)
    Q3 1.28 (1.07–1.54) 0.99 (0.86–1.14) 0.81 (0.68–0.97)
    Q4 1.38 (1.15–1.65) 1.00 (0.87–1.15) 0.89 (0.74–1.05)
95% CI, 95% confidence interval; CT, computed tomography; OR, odds ratio; PCP, primary care physician; PET, positron emission tomography.
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